BRIM8研究:维莫非尼辅助治疗已切除BRAFV600突变黑色素瘤的III期试验
BRIM8是一项随机双盲安慰剂对照III期试验,纳入498例完全切除的BRAFV600突变阳性黑色素瘤患者,评估辅助维莫非尼960mg每日两次口服52周的疗效。主要终点为无病生存期,因预设层级分析要求队列2先达到显著性,队列2未达主要终点,队列1的数值获益仅属探索性。
要点
- 维莫非尼组3-4级不良事件发生率57%,常见为角化棘皮瘤、关节痛、鳞状细胞癌等。
核心结论
- 队列2未达到无病生存期主要终点,队列1的数值获益仅可视为探索性。
- 1年辅助维莫非尼耐受性良好,但可能不是该患者群体的最佳治疗方案。
研究设计与样本
- III期国际多中心随机双盲安慰剂对照研究,纳入498例完全切除的BRAFV600突变阳性黑色素瘤成人患者。
- 按1:1随机分配至维莫非尼960mg每日两次口服或安慰剂,持续52周(13个28天周期)。
- 按病理分期和地区分层,主要终点为意向治疗人群的无病生存期,分队列评估。
主要发现
- 维莫非尼组3-4级不良事件141/247例(57%),安慰剂组37/247例(15%)。
- 维莫非尼组常见3-4级不良事件包括角化棘皮瘤24/247例(10%)、关节痛17/247例(7%)、鳞状细胞癌17/247例(7%)等。
- 严重不良事件维莫非尼组40/247例(16%),安慰剂组25/247例(10%)。
临床怎么用
- 不推荐将1年辅助维莫非尼作为已切除BRAFV600突变阳性黑色素瘤的标准治疗。
- 对于IIIC期患者,辅助维莫非尼未显示显著无病生存获益。
- 治疗决策需权衡辅助维莫非尼的毒性(3-4级不良事件57%)与潜在探索性获益。
局限性
- 预设层级分析要求队列2先达到显著性,导致队列1结果仅能视为探索性。
- 随访时间有限,中位随访约30-33个月。
- 未报告总生存数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Systemic adjuvant treatment might mitigate the high risk of disease recurrence in patients with resected stage IIC-III melanoma. The BRIM8 study evaluated adjuvant vemurafenib monotherapy in patients with resected, BRAFV600 mutation-positive melanoma. METHODS: BRIM8 was a phase 3, international, double-blind, randomised, placebo-controlled study that enrolled 498 adults (aged ≥18 years) with histologically confirmed stage IIC-IIIA-IIIB (cohort 1) or stage IIIC (cohort 2) BRAFV600 mutation-positive melanoma that was fully resected. Patients were randomly assigned (1:1) by an interactive voice or web response system to receive twice-daily adjuvant oral vemurafenib 960 mg tablets or matching placebo for 52 weeks (13 × 28-day cycles). Randomisation was done by permuted blocks (block size 6) and was stratified by pathological stage and region in cohort 1 and by region in cohort 2. The investigators, patients, and sponsor were masked to treatment assignment. The primary endpoint was disease-free survival in the intention-to-treat population, evaluated separately in each cohort. Hierarchical analysis of cohort 2 before cohort 1 was prespecified. This trial is registered with ClinicalTrials.gov, number NCT01667419. FINDINGS: The study enrolled 184 patients in cohort 2 (93 were assigned to vemurafenib and 91 to placebo) and 314 patients in cohort 1 (157 were assigned to vemurafenib and 157 to placebo). At the time of data cutoff (April 17, 2017), median study follow-up was 33·5 months (IQR 25·9-41·6) in cohort 2 and 30·8 months (25·5-40·7) in cohort 1. In cohort 2 (patients with stage IIIC disease), median disease-free survival was 23·1 months (95% CI 18·6-26·5) in the vemurafenib group versus 15·4 months (11·1-35·9) in the placebo group (hazard ratio [HR] 0·80, 95% CI 0·54-1·18; log-rank p=0·26). In cohort 1 (patients with stage IIC-IIIA-IIIB disease) median disease-free survival was not reached (95% CI not estimable) in the vemurafenib group versus 36·9 months (21·4-not estimable) in the placebo group (HR 0·54 [95% CI 0·37-0·78]; log-rank p=0·0010); however, the result was not significant because of the prespecified hierarchical prerequisite for the primary disease-free survival analysis of cohort 2 to show a significant disease-free survival benefit. Grade 3-4 adverse events occurred in 141 (57%) of 247 patients in the vemurafenib group and 37 (15%) of 247 patients in the placebo group. The most common grade 3-4 adverse events in the vemurafenib group were keratoacanthoma (24 [10%] of 247 patients), arthralgia (17 [7%]), squamous cell carcinoma (17 [7%]), rash (14 [6%]), and elevated alanine aminotransferase (14 [6%]), although all keratoacanthoma events and most squamous cell carcinoma events were by default graded as grade 3. In the placebo group, grade 3-4 adverse events did not exceed 2% for any of the reported terms. Serious adverse events were reported in 40 (16%) of 247 patients in the vemurafenib group and 25 (10%) of 247 patients in the placebo group. The most common serious adverse event was basal cell carcinoma, which was reported in eight (3%) patients in each group. One patient in the vemurafenib group of cohort 2 died 2 months after admission to hospital for grade 3 hypertension; however, this death was not considered to be related to the study drug. INTERPRETATION: The primary endpoint of disease-free survival was not met in cohort 2, and therefore the analysis of cohort 1 showing a numerical benefit in disease-free survival with vemurafenib versus placebo in patients with resected stage IIC-IIIA-IIIB BRAFV600 mutation-positive melanoma must be considered exploratory only. 1 year of adjuvant vemurafenib was well tolerated, but might not be an optimal treatment regimen in this patient population. FUNDING: F Hoffman-La Roche Ltd.
引用
- Maio M, Lewis K, Demidov L, et al. Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. Lancet Oncol. 2018. PMID: 29477665. doi:10.1016/S1470-2045(18)30106-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。